论文部分内容阅读
目的:探究腔内注射紫杉醇脂质体联合复方苦参注射液,配合口服益气养胃汤治疗恶性腹腔积液的临床疗效。方法:我科98例晚期胃癌伴有腹腔积液患者,随机分为3组,分别应用腹腔内注射紫杉醇脂质体(A组)、腹腔内注射紫杉醇脂质体联合复方苦参注射液(B组)、腹腔内注射紫杉醇脂质体联合复方苦参注射液及口服益气养胃汤(C组),比较3组临床疗效及副作用。结果:A组总有效率54.54%,B组总有效率78.13%,C组总有效率81.82%优于A、B组,差异具有统计学意义(P<0.05)。毒副反应方面,C组恶心呕吐症状与A、B组相比,差异具有统计学意义(P<0.05)。治疗后,C组生活质量评分优于A、B组(P<0.05)。结论:紫杉醇脂质体联合复方苦参注射液、益气养胃汤,针对晚期胃癌伴有恶性腹腔积液患者临床治疗效果显著,患者生活质量改善明显,可有效延长患者生存期,安全可靠,值得推广应用。
Objective: To investigate the clinical efficacy of intra-ocular injection of paclitaxel liposomes in combination with compound Kushen injection in combination with oral Yiqi Yangwei Decoction in the treatment of malignant ascites. Methods: A total of 98 patients with advanced gastric cancer with ascites were randomly divided into three groups. The mice were randomly divided into three groups: paclitaxel liposome (intraperitoneal injection), intraperitoneal injection of paclitaxel liposome combined with compound Kushen injection (B) Group), intraperitoneal injection of paclitaxel liposomes combined with Compound Kushen Injection and oral Yiqi Yangwei Decoction (C group), the clinical efficacy and side effects were compared between the three groups. Results: The total effective rate in group A was 54.54%. The total effective rate in group B was 78.13%. The total effective rate in group C was 81.82%. The difference was statistically significant (P <0.05). Toxic side effects, group C nausea and vomiting symptoms compared with the A, B group, the difference was statistically significant (P <0.05). After treatment, the quality of life in group C was better than that in group A and B (P <0.05). Conclusion: paclitaxel liposomes combined with Compound Kushen Injection, Yiqi Yangwei Decoction for patients with advanced gastric cancer associated with malignant ascites significant clinical treatment, patients with significant improvement in quality of life, which can effectively extend the survival of patients, safe and reliable, Worth promoting application.